Pediatric-type Myoid Neoplasms of Somatic Soft Tissue: A Clinicopathological and Molecular Genetic Study of 78 Tumors, Highlighting Indolent Clinical Behavior and Frequent SRF Gene Rearrangements.
Erin L J Alston, Judith Jebastin Thangaiah, Ross Rowsey, Christopher D Hofich, Troy Gliem, Andrea C Bakker, Mark Sabbagh, Alanna J Church, David J Papke, Andrew L Folpe, Alyaa Al-Ibraheemi
{"title":"Pediatric-type Myoid Neoplasms of Somatic Soft Tissue: A Clinicopathological and Molecular Genetic Study of 78 Tumors, Highlighting Indolent Clinical Behavior and Frequent SRF Gene Rearrangements.","authors":"Erin L J Alston, Judith Jebastin Thangaiah, Ross Rowsey, Christopher D Hofich, Troy Gliem, Andrea C Bakker, Mark Sabbagh, Alanna J Church, David J Papke, Andrew L Folpe, Alyaa Al-Ibraheemi","doi":"10.1016/j.modpat.2025.100722","DOIUrl":null,"url":null,"abstract":"<p><p>Soft tissue tumors with smooth muscle differentiation are rare in pediatric patients. Despite often showing morphologic features sufficient for classification as \"leiomyosarcoma\" in adults (e.g., high cellularity, mitotic activity), clinical follow-up has shown only indolent behavior. The pathological features of recently reported SRF-rearranged \"cellular myofibromas/myopericytomas\", typically occurring in children, overlap with those of true smooth muscle tumors. We studied a large series of pediatric tumors with morphologic and immunohistochemical evidence of smooth muscle differentiation, with the goals of better understanding their natural history and molecular genetic features. Seventy-eight tumors were identified occurring in 45 males and 33 females, with a median age of 10 years. Clinical follow-up (50 patients; median 45.5 months) disclosed local recurrence in 7 patients (15%). No metastases or deaths due to disease occurred. Group 1 (73/78) tumors consisted of cellular fascicles of mildly to at most moderately atypical, bland, ovoid to spindled cells with distinctly eosinophilic cytoplasm, appreciable mitotic activity (median 5/50 HPF) and no necrosis. Group 2 tumors (5/78) showed greater cellularity, significant nuclear pleomorphism, and brisk mitotic activity (median 59/50 HPF). Subsets of group 1 tumors harbored SRF rearrangements (16/47) and all group 2 tumors showed TP53 biallelic inactivation (5/5). SRF fusion partners included CITED1, NCOA2, C3orf62, RELA, ARGFXP1, ARNTI2, ICA1L, and unknown (n=1). We conclude that the prognosis for pediatric tumors with smooth muscle differentiation that fall into group 1 is excellent. SRF rearrangements are present in a significant minority of tumors, typically showing features of smooth muscle, rather than myopericytic differentiation. A smaller subset with more worrisome morphologic features harbor biallelic inactivation of TP53. To emphasize their unique features, we propose the term \"pediatric-type myoid neoplasms of somatic soft tissue,\" rather than simply \"leiomyoma\" or \"leiomyosarcoma\" for group 1 tumors and the designation of leiomyosarcoma in children should be limited to group 2 tumors.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100722"},"PeriodicalIF":7.1000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.modpat.2025.100722","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Soft tissue tumors with smooth muscle differentiation are rare in pediatric patients. Despite often showing morphologic features sufficient for classification as "leiomyosarcoma" in adults (e.g., high cellularity, mitotic activity), clinical follow-up has shown only indolent behavior. The pathological features of recently reported SRF-rearranged "cellular myofibromas/myopericytomas", typically occurring in children, overlap with those of true smooth muscle tumors. We studied a large series of pediatric tumors with morphologic and immunohistochemical evidence of smooth muscle differentiation, with the goals of better understanding their natural history and molecular genetic features. Seventy-eight tumors were identified occurring in 45 males and 33 females, with a median age of 10 years. Clinical follow-up (50 patients; median 45.5 months) disclosed local recurrence in 7 patients (15%). No metastases or deaths due to disease occurred. Group 1 (73/78) tumors consisted of cellular fascicles of mildly to at most moderately atypical, bland, ovoid to spindled cells with distinctly eosinophilic cytoplasm, appreciable mitotic activity (median 5/50 HPF) and no necrosis. Group 2 tumors (5/78) showed greater cellularity, significant nuclear pleomorphism, and brisk mitotic activity (median 59/50 HPF). Subsets of group 1 tumors harbored SRF rearrangements (16/47) and all group 2 tumors showed TP53 biallelic inactivation (5/5). SRF fusion partners included CITED1, NCOA2, C3orf62, RELA, ARGFXP1, ARNTI2, ICA1L, and unknown (n=1). We conclude that the prognosis for pediatric tumors with smooth muscle differentiation that fall into group 1 is excellent. SRF rearrangements are present in a significant minority of tumors, typically showing features of smooth muscle, rather than myopericytic differentiation. A smaller subset with more worrisome morphologic features harbor biallelic inactivation of TP53. To emphasize their unique features, we propose the term "pediatric-type myoid neoplasms of somatic soft tissue," rather than simply "leiomyoma" or "leiomyosarcoma" for group 1 tumors and the designation of leiomyosarcoma in children should be limited to group 2 tumors.
期刊介绍:
Modern Pathology, an international journal under the ownership of The United States & Canadian Academy of Pathology (USCAP), serves as an authoritative platform for publishing top-tier clinical and translational research studies in pathology.
Original manuscripts are the primary focus of Modern Pathology, complemented by impactful editorials, reviews, and practice guidelines covering all facets of precision diagnostics in human pathology. The journal's scope includes advancements in molecular diagnostics and genomic classifications of diseases, breakthroughs in immune-oncology, computational science, applied bioinformatics, and digital pathology.